TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
+6.06%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$195M
AUM Growth
+$195M
(-60%)
Cap. Flow
-$274M
Cap. Flow
% of AUM
-140.53%
Top 10 Holdings %
Top 10 Hldgs %
73.17%
Holding
37
New
9
Increased
2
Reduced
10
Closed
15
Top Buys
| 1 |
McKesson
MCK
|
$18.1M |
| 2 |
Soleno Therapeutics
SLNO
|
$16.8M |
| 3 |
Cigna
CI
|
$10.9M |
| 4 |
Gilead Sciences
GILD
|
$10M |
| 5 |
Illumina
ILMN
|
$9.58M |
Top Sells
| 1 |
Zimmer Biomet
ZBH
|
$39M |
| 2 |
Natera
NTRA
|
$32.1M |
| 3 |
argenx
ARGX
|
$23.9M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$21.1M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$20.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cigna
CI
$80.3B
| $24.3M | 12.48% | 73,905 +33,095 | +81% | +$10.9M |
|
|
2
McKesson
MCK
$85.4B
| $18.1M | 9.3% | +26,944 | New | +$18.1M |
|
|
3
Soleno Therapeutics
SLNO
$3.6B
| $16.8M | 8.61% | +234,920 | New | +$16.8M |
|
|
4
Teva Pharmaceuticals
TEVA
$21.1B
| $16.3M | 8.37% | 1,061,008 -1,362,108 | -56% | -$20.9M |
|
5
Inspire Medical Systems
INSP
$2.77B
| $12.6M | 6.44% | 78,812 -71,976 | -48% | -$11.5M |
|
6
Madrigal Pharmaceuticals
MDGL
$9.76B
| $12.5M | 6.44% | 37,869 -9,603 | -20% | -$3.18M |
|
7
Axsome Therapeutics
AXSM
$6.05B
| $11.8M | 6.06% | 101,240 -148,529 | -59% | -$17.3M |
|
|
8
argenx
ARGX
$43.6B
| $10.6M | 5.42% | 17,844 -40,414 | -69% | -$23.9M |
|
|
9
Gilead Sciences
GILD
$140B
| $10M | 5.14% | +89,453 | New | +$10M |
|
|
10
Illumina
ILMN
$15.8B
| $9.58M | 4.91% | +120,729 | New | +$9.58M |
|
11
Insmed
INSM
$28.8B
| $7.77M | 3.99% | +101,859 | New | +$7.77M |
|
12
Nuvalent
NUVL
$5.52B
| $6.8M | 3.49% | +95,825 | New | +$6.8M |
|
13
Merus
MRUS
$4.98B
| $6.6M | 3.39% | 156,915 -190,388 | -55% | -$8.01M |
|
14
GeneDx Holdings
WGS
$3.72B
| $5.15M | 2.64% | 58,145 -69,422 | -54% | -$6.15M |
|
15
Ascendis Pharma
ASND
$11.8B
| $5.04M | 2.59% | +32,325 | New | +$5.04M |
|
|
BPMC
16
DELISTED
Blueprint Medicines
BPMC
| $4.43M | 2.27% | +50,000 | New | +$4.43M |
|
17
Evolus
EOLS
$494M
| $3.87M | 1.99% | 321,802 -420,772 | -57% | -$5.06M |
|
18
Vera Therapeutics
VERA
$1.38B
| $3.61M | 1.85% | +150,207 | New | +$3.61M |
|
19
Stevanato
STVN
$6.28B
| $3.59M | 1.84% | 175,681 -946,123 | -84% | -$19.3M |
|
20
Praxis Precision Medicines
PRAX
$958M
| $3.17M | 1.63% | 83,659 +46,390 | +124% | +$1.76M |
|
21
Korro Bio
KRRO
$217M
| $2.24M | 1.15% | 128,381 -15,835 | -11% | -$276K |
|
22
Femasys
FEMY
$11.6M
| $38.3K | 0.02% | 30,606 | – | – |
|
|
AVDL
23
Avadel Pharmaceuticals
AVDL
$1.43B
| – | – | -1,937,984 | Closed | -$20.4M |
|
24
Biohaven
BHVN
$1.63B
| – | – | -140,220 | Closed | -$5.24M |
|
25
Bristol-Myers Squibb
BMY
$96B
| – | – | -355,366 | Closed | -$20.1M |
|